Sentiment Trading

Salarius Pharmaceuticals Inc faces significant financial challenges, including a negative P/E ratio and declining stock price, raising concerns about its ability to achieve its ambitious oncology goals.

Salarius Pharmaceuticals Inc. has received a Nasdaq listing extension and announced plans for a public offering, leading to a 110% surge in its stock price and increased investor interest.

Salarius Pharmaceuticals’ stock price surged 110% after receiving a conditional Nasdaq listing extension, but the company’s financial challenges and mixed investor sentiment raise questions about its long-term viability.